The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives
O Uher, K Hadrava Vanova, D Taïeb… - Endocrine …, 2024 - academic.oup.com
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors derived
from neural crest cells from adrenal medullary chromaffin tissues or extra-adrenal …
from neural crest cells from adrenal medullary chromaffin tissues or extra-adrenal …
[HTML][HTML] Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction
Rationale: The passage of antibodies through the blood-brain barrier (BBB) and the blood-
tumoral barrier (BTB) is determinant not only to increase the immune checkpoint inhibitors …
tumoral barrier (BTB) is determinant not only to increase the immune checkpoint inhibitors …
Brain delivery enabled by transient blood-brain barrier disruption induced by regadenoson: a PET imaging study
B Hosten, S Goutal, S Leterrier, C Corvo… - Expert Opinion on …, 2024 - Taylor & Francis
Background Regadenoson, an agonist of adenosine A2 receptors, enables transient blood-
brain barrier (BBB) disruption. The relevance of regadenoson as a pharmacological strategy …
brain barrier (BBB) disruption. The relevance of regadenoson as a pharmacological strategy …
[HTML][HTML] Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice
L Meyblum, C Chevaleyre, S Susini… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Despite the promising efficacy of immune checkpoint blockers (ICB), tumor
resistance and immune-related adverse events hinder their success in cancer treatment. To …
resistance and immune-related adverse events hinder their success in cancer treatment. To …
[89Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models
Simple Summary Triple-negative breast cancer is characterized by a lack of targetable
treatment receptors and current standard of care options, such as radiation therapy and …
treatment receptors and current standard of care options, such as radiation therapy and …
Fluorine-18 and Radiometal Labeling of Biomolecules via Disulfide Rebridging
M Richard, S Martin Aubert, C Denis… - Bioconjugate …, 2023 - ACS Publications
Biomolecules labeled with positron-emitting radionuclides like fluorine-18 or radiometals
like copper-64 and zirconium-89 are increasingly employed in nuclear medicine for …
like copper-64 and zirconium-89 are increasingly employed in nuclear medicine for …
Pharmacokinetics and Biodistribution of 89Zr-Miltuximab and Its Antibody Fragments as Glypican-1 Targeting Immuno-PET Agents in Glioblastoma
Glioblastoma (GBM) is the most aggressive form of primary brain cancer, accounting for
about 85% of all primary central nervous system (CNS) tumors. With standard treatment …
about 85% of all primary central nervous system (CNS) tumors. With standard treatment …
89Zr-ImmunoPET for the Specific Detection of EMP2-Positive Tumors
Abstract Epithelial membrane protein-2 (EMP2) is upregulated in a number of tumors and
therefore remains a promising target for mAb-based therapy. In the current study, image …
therefore remains a promising target for mAb-based therapy. In the current study, image …
ImmunoPET imaging–based pharmacokinetic profiles of an antibody and its Fab targeting endothelin A receptors on glioblastoma stem cells in a preclinical orthotopic …
M Hautiere, D Vivier, D Pineau, C Denis… - European Journal of …, 2023 - Springer
Background The resistance of glioblastoma stem cells (GSCs) to treatment is one of the
causes of glioblastoma (GBM) recurrence. Endothelin A receptor (ETA) overexpression in …
causes of glioblastoma (GBM) recurrence. Endothelin A receptor (ETA) overexpression in …
[HTML][HTML] Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab
Breast cancer (BrCa) ranks as the most prevalent malignant neoplasm affecting women
worldwide. The expression of programmed death-ligand 1 (PD-L1) in BrCa has recently …
worldwide. The expression of programmed death-ligand 1 (PD-L1) in BrCa has recently …